Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Getafe – page 167

3 196 clinical trials in Getafe, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Getafe at a glance
3 196
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 196 trials in Getafe

Open in trial search

Cardiac failure chronic+1

Not recruiting

Study on Managing Heart Failure and Kidney Disease in Elderly Patients with High Potassium Risk Using Sodium Zirconium Cyclosilicate

Registered drugNo placebo
Countries:SpainSpain
  • Participants:65+ years
  • Substances:Sodium Zirconium Cyclosilicate
  • Sponsor:Hospital Clinico Universitario De Valencia

Head and neck cancer metastatic

Not recruiting

Study of eftilagimod alpha with pembrolizumab combination therapy for patients with metastatic head and neck cancer who have not received previous treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Eftilagimod Alfa
  • Sponsor:Immutep

Familial hypertriglyceridaemia+1

Not recruiting

Study on the Effects of ISIS 678354 in Patients with Familial Chylomicronemia Syndrome (FCS)

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Ionis Pharmaceuticals Inc.

HIV infection

Not recruiting

Study of IMC-M113V for Patients with Chronic HIV Infection Who Are Virologically Suppressed

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Immunocore Limited

Neoplasm malignant

Not recruiting

Study of PM14 and Irinotecan for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Irinotecan
  • Sponsor:Pharma Mar S.A.

Endometrial cancer recurrent+4

Not recruiting

Study on the Safety and Effectiveness of IMGN151 for Women with Recurrent Endometrial and Ovarian Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Brimonidine Tartrate
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Guselkumab for Patients with Fistulizing Perianal Crohn's Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Non-small cell lung cancer

Not recruiting

Study for Patients with Advanced Non-Small Cell Lung Cancer Worsened by Osimertinib Treatment, Using Selumetinib and Drug Combination

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Idiopathic inflammatory myopathy

Not recruiting

Study on the Effects and Safety of Efgartigimod PH20 SC for Adults with Active Idiopathic Inflammatory Myopathy

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Acute myeloid leukaemia

Not recruiting

Study of venetoclax and azacitidine combination treatment for acute myeloid leukemia patients with measurable residual disease after chemotherapy or before stem cell transplant

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Grupo Cooperativo De Estudio Y Tratamiento De Las Leucemias Agudas Y Mielodisplasias

Plasma cell myeloma

Not recruiting

Study of Talquetamab and Teclistamab for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

Bladder cancer

Not recruiting

Study on UGN-103 (Mitomycin) for Treating Low Grade Nonmuscle Invasive Bladder Cancer in Patients at Intermediate Risk of Recurrence

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Poloxamer 407
  • Sponsor:Urogen Pharma Ltd.

Other cities in Spain

The busiest research cities in the country

All 203 cities in Spain

Clinical research in Getafe

What the registry says about research in the country

01 Respiratory & Infectious Diseases

Groundbreaking research focusing on pneumococcal disease prevention and treatment of acute respiratory distress syndrome, including innovative vaccine development and therapeutic approaches.

  • Pneumococcal Vaccines
  • ARDS Treatment
  • Community-Acquired Pneumonia

Studies aim to enhance protection against respiratory infections and improve patient outcomes in severe cases.

02 Neurological Disorders

Innovative clinical trials exploring treatments for multiple sclerosis and Menière's disease, focusing on disease modification and symptom management.

  • MS Treatment Comparisons
  • Inner Ear Disorders
  • Neurological Therapeutics

Research aims to improve quality of life and disease management for patients with chronic neurological conditions.

03 Cardiovascular & Renal Studies

Comprehensive research into chronic renal disease, pulmonary embolism, and vascular conditions, evaluating new therapeutic approaches.

  • Renal Disease Management
  • Pulmonary Embolism Treatment
  • Vascular Health

Studies focus on improving outcomes in patients with complex cardiovascular and kidney conditions.

04 Oncology & Specialized Care

Advanced research in prostate cancer treatment and management of vitiligo, exploring innovative therapeutic options.

  • Cancer Treatment
  • Dermatological Conditions
  • Specialized Therapies

Trials aim to develop more effective treatments for both oncological and dermatological conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.